Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers

Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID,  is the subject of this episode.This episode is accredited for CPE.  For CE details and to claim credit click here:  https://bit.ly/3hn191p See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram